Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
2026.10.02
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
2026.10.02
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
2026.09.30
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
2026.09.30
Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
2026.09.29
Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology
2026.09.29
CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights
2026.09.29
Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference
2026.09.29
2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies
2026.09.29
CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing
2026.09.28
Posted inUncategorized

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Posted by By Peng Longmei 2026.10.02
Continue Reading
Posted inUroStream

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Posted by By Mourabit Halima 2026.10.02
Continue Reading
CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

Posted by By Mourabit Halima 2025.09.04
Editor's Note: At this conference, Professor Alexey Danilov (Professor of Hematology, Associate Director of the Lymphoma Center, and Director of the Early Therapeutics Program at City of Hope National Medical…
Read More
EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

Posted by By Peter W. PENG 2025.09.04
Editor's Note: At ICML conference, Professor Jose C. Villa Boas from Rochester, USA, was invited to present an oral report titled "EO2463 Peptide Immunotherapy in Combination with Lenalidomide and Rituximab…
Read More
New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

Posted by By Mourabit Halima 2025.09.04
Editor's Note: The conference brought together top experts in lymphoma research from home and abroad, engaging in in-depth discussions on cutting-edge topics such as novel molecular targeted therapies and cell…
Read More
Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The 18th International Conference on Malignant Lymphoma (ICML) was held, gathering top experts in the lymphoma field in Lugano. At the prestigious John Ultmann Memorial Lecture, Professor Emanuele…
Read More
A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

Posted by By Ren Jiamo 2025.09.03
Editor's Note: In 2025, the International Conference on Malignant Lymphoma (ICML) convened in Switzerland, bringing together the world's leading experts in the field of lymphoma. At the conference, Professor David…
Read More
The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

Posted by By Peng Longmei 2025.09.03
Editor's Note: The International Hematologic Oncology Pathology Conference brought together top experts in hematopathology research from home and abroad for in-depth discussions on cutting-edge topics such as lymphoma diagnosis, classification…
Read More

Professor Bruce D. Cheson on Breakthroughs in Lymphoma Treatment: Innovation Pathways and Future Vision丨EHA 2025

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The conference focused on the latest diagnostic and therapeutic advances in lymphoid system tumors, providing a cutting-edge academic exchange platform for the global oncology community. At this prestigious…
Read More
Professor Yuzhu Shi: The Comprehensive Value of Abdominal CT in Managing Post-Transplant Complications丨13th Lu Daopei Hematology Conference

Professor Yuzhu Shi: The Comprehensive Value of Abdominal CT in Managing Post-Transplant Complications丨13th Lu Daopei Hematology Conference

Posted by By Peter W. PENG 2025.09.03
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Read More
Professor Hui Wang: Advancing MRD Detection in AML—From Standardization and Automation Toward Personalized Treatment

Professor Hui Wang: Advancing MRD Detection in AML—From Standardization and Automation Toward Personalized Treatment

Posted by By Mourabit Halima 2025.09.03
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Read More
Professor Tong Wang Analyzes the Clinical Challenges of Multilineage Involvement in BCR::ABL1-Positive B-ALL丨13th Lu Daopei Hematology Conference

Professor Tong Wang Analyzes the Clinical Challenges of Multilineage Involvement in BCR::ABL1-Positive B-ALL丨13th Lu Daopei Hematology Conference

Posted by By Peter W. PENG 2025.09.02
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
  • Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
  • Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
  • 2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
  • Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inUncategorized
    Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
    Posted by By Peng Longmei 2026.10.02
    Posted inUroStream
    Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
    Posted by By Mourabit Halima 2026.10.02
    Posted inUroStream
    Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
    Posted by By Peter W. PENG 2026.09.30
    Posted inUroStream
    2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
    Posted by By Mourabit Halima 2026.09.30
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied